TickerFacts.

Cannapharmarx, Inc. (CPMD): Cost of Revenue

Annual figures by period end, from SEC filings.

$3.45M
Year ended 2025-12-31
$3.21M
Trailing 12 months to 2026-06-30
$3.76M2023-12-31: $02024-12-31: $3.76M2025-12-31: $3.45M$3.45M
2023-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$3.45M-8.2%2026-03-31, From 2025-01-01
2024-12-31$3.76Mn/a2026-03-31, From 2024-01-01
2023-12-31$0n/a2025-04-10, From 2023-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Cannapharmarx, Inc. (CPMD)2025-12-31$3.45M-8.2%
NRX Pharmaceuticals, Inc. (NRXP)2025-12-31$505.0Kn/a
IGC Pharma, Inc. (IGC)2025-03-31$652.0K+6.5%
Longeveron Inc. (LGVN)2025-12-31$396.0K-22.0%
China SXT Pharmaceuticals, Inc. (SXTC)2026-03-31$889.4K-35.2%
Bespoke Extracts, Inc. (BSPK)2024-12-31$664.5K+50.2%
Dare Bioscience, Inc. (DARE)2025-12-31$295.8Kn/a
60 Degrees Pharmaceuticals, Inc. (SXTP)2025-12-31$781.7K+103.2%
Bio Essence Corp (BIOE)2025-12-31$469.2K+339.0%

Compare CPMD, NRXP, IGC, LGVN side by side · Screen every company in Pharmaceutical Preparations ↗